Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab and Lenalidomide in Untreated Follicular Lymphoma
NCT02871219Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab and lenalidomide in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 71 months. Started Dec 2016; status: completed.
02
Drugs
obinutuzumablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02871219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871219.